Escolar Documentos
Profissional Documentos
Cultura Documentos
EMERGING EQUITIES
FEBRUARY 2018
This product is suitable for investors who are seeking*
• Capital appreciation over long term
• Investing in companies having a large market capitalization
*Investors should consult their financial advisers if in doubt about whether the product is suitable
Source: ICRA MFI Explorer
15000
10000
25000
0
5000
20000
30000
Jan-03
MID CAP OUTPERFORMANCE
May-03
Aug-03
Dec-03
Apr-04
Aug-04
Dec-04
Apr-05
Aug-05
Dec-05
Nifty 50 TRI
Apr-06
Aug-06
Dec-06
Apr-07
Aug-07
Dec-07
Apr-08
Nifty 50 TRI
Aug-08
Nov-10
From Date
Mar-11
Jul-11
Nov-11
Mar-12
Jul-12
Nov-12
To Date
Mar-13
14358.71
Nifty Free Float Midcap 100 TRI
25008.10
28-Feb-18
Jul-13
Nov-13
Mid caps tend to outperform large caps
Mar-14
Jul-14
Oct-14
Feb-15
CAGR
17.65%
23.64%
Jun-15
Oct-15
Feb-16
Jun-16
Oct-16
Feb-17
Jun-17
Oct-17
Feb-18
MID CAP PERFORMANCE
2000 8
GDP %
1500 6
1000 4
500 2
0 0
Index Values
2000
GDP %
GDP %
1500 9.00 6.00
1500
1000 4.00
8.00 1000
500 500 2.00
0 7.00 0 0.00
Jul-07
Jul-08
Apr-09
Apr-07
Oct-07
Oct-06
Apr-08
Oct-08
Jan-07
Jan-09
Jan-08
Nifty 50 TRI Nifty Free Float Midcap 100 TRI GDP Nifty 50 TRI Nifty Free Float Midcap 100 TRI GDP
Every trough is followed by an expansion phase. Staying invested in Midcaps even during
economic slowdown is advantageous, to reap the benefits of economic revival.
Source: Bloomberg, MFIE, ICRAOnline. Past performance may or may not be sustained in future
MID CAP PERFORMANCE
CY 2004 13 28
CY 2005 40
40
CY 2006 31 42
CY 2007 56 79
CY 2008 -58 -50
CY 2009 76 103
CY 2010 21
20 9 out of 15 times
CY 2011 -29-23
41
Midcap
CY 2012 29
CY 2013 -3 8 outperformed
CY 2014 33 59
CY 2015 9 Large Caps
-3
CY 2016 59
CY 2017 30 49
CY 2018 * -7 0
60.00
40.00
20.00
0.00
-20.00
Dec-05
May-07
Dec-06
Feb-11
Nov-13
Oct-15
Mar-10
Nov-14
Sep-16
Jan-12
Jul-12
Jun-06
Apr-09
Mar-16
Mar-17
Feb-18
Nov-07
Apr-08
Oct-08
Dec-12
May-14
Sep-09
Aug-10
Aug-11
Jun-13
Aug-17
Apr-15
Probability of Outperformance of Midcap over Nifty
28%
Source: ICRA MFI Explorer, Rolling Return (CAGR) for the above periods. Data as on 28th Feb’18
LONG TERM PERFORMANCE
Nov-11
May-09
Dec-09
Oct-13
Nov-14
Sep-10
Jan-11
Feb-12
Mar-13
Jan-14
Oct-16
Feb-15
Sep-15
May-15
Mar-16
Nov-17
Jan-17
Feb-18
Apr-08
Mar-10
Jul-11
Aug-09
May-12
Dec-12
Jul-14
Dec-15
Jan-08
Oct-08
Feb-09
Aug-12
Jun-13
Jun-16
Jun-10
Apr-11
Apr-17
Aug-17
Apr-14
Probability of Outperformance of Midcap over Nifty
16%
Source: ICRA MFI Explorer, Rolling Return (CAGR) for the above periods. Data as on 28th Feb’18
LONG TERM PERFORMANCE
30
Daily 10 year Rolling Return (%)
25
Nifty 50 TRI Nifty Free Float Midcap 100 TRI
20
15
10
0
Jan-13
Feb-13
Oct-13
Sep-15
Nov-15
Oct-16
Oct-17
Nov-13
Jan-14
Oct-14
Mar-14
Feb-15
Jan-17
Sep-17
Jul-14
Jan-16
Mar-17
May-17
Jul-17
May-15
Jul-15
Mar-16
Feb-18
May-14
Dec-14
Dec-16
Dec-17
Jun-13
Jun-16
Apr-13
Aug-13
Aug-14
Apr-15
Apr-16
Aug-16
Probability of Outperformance of Midcap over Nifty
1%
Outperformance Underperformance
99%
Source: ICRA MFI Explorer, Rolling Return (CAGR) for the above periods. Data as on 28th Feb’18
RIISK REWARD MATRIX
Since the risk associated
with mid & small cap funds is
high, the potential to
generate better returns is
also high Thematic Funds
Index Funds
Balanced Fund
RETURN
LOW MEDIUM HIGH
INVESTMENT PHILOSOPHY
Bottom up
stock
picking
Canara
Robeco
Emerging
Equities
Growth at
Reasonable
Price
(GARP)
• Intrinsic Value
• High Growth Potential
• Healthy Financial
• Market leadership
Business Valuation
Management
Technological
Edge
Distribution &
Logistics High Barriers to
Entry
Stocks
likely
beneficiary
of
Goods &
Services Tax
PORTFOLIO CONSTRUCT
Power Media
RECENT TRENDS
Value Migration
✓ Auto ancillaries – Low end to high end and High cost to Low cost
✓ Aspiration & ‘Premium’isation - Multiplex, Consumer durables and non-durables
✓ Physical assets to financial assets – Financial saving mobilisers such as MFs, Wealth desks, Private
Equities
✓ Generic molecules to complex R&D based molecules – Niche R&D driven pharma & specialty chemical
companies
Feb’18
No of Stocks in the Portfolio 65
Highest Stock Exposure in the Portfolio 3.83%
Top 3 sector exposure 34.00%
Top 10 holdings 28.03%
Top 10 Holdings Industry Classification % of Net Assets Top 5 Sector break up (% to NAV)
Chemicals | 5.58%
Piramal Enterprises Ltd Pharmaceuticals 2.63%
0% 2% 4% 6% 8% 10% 12% 14%
Container Corporation Of
Transportation 2.55% Asset Allocation
India Ltd
3.54
Large Cap
Growth Blend Value
12.22 12.61
Mid Cap
Large Cap Mid Cap Small Cap
Small Cap
Quantitative Information
Criteria Values
Standard Deviation 17.34
Portfolio Beta 0.97
Portfolio Turnover Ratio 0.54 times
R-Squared 0.86
Sharpe Ratio 0.64
Canara Robeco Emerging Equities 1 year 3 years 5 years 5 years 10 years Since Inception
Total Amt invested (INR) 1,20,000 3,60,000 6,00,000 8,40,000 12,00,000 15,60,000
Market Value (INR) 1,29,800 4,93,916 12,19,991 22,07,522 45,42,345 69,27,256
Investment date is taken to be 1st of the month or subsequent day if 1st is a holiday and investment of Rs.10,000 is taken. Returns are as on 28th Feb’18 and are CAGR. The calculations are based on the
regular growth plan NAVs. Past performance may or may not be sustained in the future. Scheme Benchmark# , Additional benchmark##. Inception Date: March 11, 2005
PRODUCT POSITIONING
CORE PORTFOLIO
Large Cap CR Large Cap +
SATELITE PORTFOLIO
Mid &
CR Emerging Equities
Small Cap
NEED BASED
ELSS CR Equity TaxSaver
Bottom-up stock picking employed on Mid Cap & Small Cap Companies endeavors to select the best among
the emerging companies form a part of portfolio
Endeavour to identify companies which have the potential to become leaders of tomorrow in their
respective sectors
Bias towards identifying Mid Cap Companies in the portfolio helps investors benefit from better growth
prospects of those companies
Taking a Long Term View: The fund invests with a long term view. The aim is to stay away from herd
behaviour, chasing short term profits, running after certain market spurs. Such short term approach tends
to be very risk and may not pay off in the long term
FUND FACTS
To generate capital appreciation by primarily investing in diversified mid cap stocks. However, there can
Investment Objective
be no assurance that the investment objective of the Scheme will be realized.
The information used towards formulating the outlook have been obtained from sources published by third parties. While such
publications are believed to be reliable, however, neither the AMC, its officers, the trustees, the Fund nor any of their affiliates or
representatives assume any responsibility for the accuracy of such information. CRMF, its sponsors, its trustees, CRAMC, its
employees, officer, directors, etc assume no financial liability whatsoever to the user of this document. Mutual Fund
Investments are subject to market risk. Investors are requested to read the Scheme related documents carefully before
investing.
Mutual Fund investments are subject to market risks, read all Scheme related documents carefully.